Drug intelligence / Profile preview

methotrexate + trastuzumab

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous, Oral

Overview

Methotrexate + trastuzumab is a combination therapy used for HER2-positive breast cancer. Trastuzumab is a monoclonal antibody that targets the HER2 receptor, which is overexpressed in approximately 20-30% of breast cancers. Methotrexate is an antifolate drug that inhibits purine de novo synthesis, impeding DNA synthesis and repair. The combination has shown efficacy in metastatic breast cancer patients, including those previously treated with trastuzumab. Methotrexate can enhance the cytotoxicity of trastuzumab-based therapies by acting as a radiosensitizer.

Targets

DHFR (Dihydrofolate reductase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on methotrexate + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on methotrexate + trastuzumab.

Explore the full profile